Commentary: Oncologic drugs in patients with organ dysfunction: a summary.
about
Cancer and liver cirrhosis: implications on prognosis and managementA survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directionsToxicities of gemcitabine in patients with severe hepatic dysfunction.Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application.Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinomaHepatotoxicity of molecular targeted therapy.Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective.Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I StudiesAn evaluation of hepatotoxicity in breast cancer patients receiving injection Doxorubicin.Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.Management of hematological malignancies in patients affected by renal failure.Treatment of elderly patients with stage IV non-small-cell lung cancer.Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives.Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease.Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase.The oncologic burden of hepatitis C virus infection: A clinical perspective.Complete response of a metastatic gastroesophageal adenocarcinoma on irinotecan-based chemotherapy in a dialysis patient.Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report.Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study.Therapeutic options for patients with lymphoma and liver dysfunction or failure during mechlorethamine shortage.Guidelines for treatment of renal injury during cancer chemotherapy 2016.Start using a checklist, PRONTO: Recommendation for a standard review process for chemotherapy orders.Protective Effect of Boswellic Acids against Doxorubicin-Induced Hepatotoxicity: Impact on Nrf2/HO-1 Defense Pathway.Treatment of Elderly Patients with Colorectal Cancer.
P2860
Q28068579-4792A79D-0D55-451D-99F6-85E2E55E2F50Q30491777-B0455D0B-0060-483D-969F-FCB37BD03C40Q33388646-8440D07B-6DA4-4F1E-9E4E-435A154F1929Q33553308-738B7C9A-4EB6-40D3-B691-877B946A78D3Q35014219-08257026-15BB-4697-8C31-C463FD78A3ACQ35648962-EC14B276-4F2E-43EC-AA7E-CCBFD6FAA978Q36307995-35272DE6-E9C4-4171-B834-BD0BBDC6894AQ37166427-B1482BE2-00AE-4759-8557-EEB5DFD6A31CQ37634629-07BF3E45-6175-461A-BA6F-A9825EB37156Q37639225-DB3384A1-CEBF-4DE6-BFFF-576F53DCF768Q37854710-CEF4D043-1333-4AFB-9D65-CBBAC87AE243Q37965641-127F787C-F381-4999-BCA3-F379388B1462Q38242272-D147F088-340C-477D-87CD-1048C0CA85D1Q38248974-2D0833D7-5648-4328-A887-BE6211070EDEQ38287050-FCEE7328-DC57-4663-9106-C92CB8952259Q38761339-A67267FE-4D7A-4FF1-B5F0-C31A363F0771Q39418450-95240FA4-B9F2-457F-B465-D891BBD5B8E4Q41852113-CF3FEC55-2165-4736-BFFD-C65C6A1088F6Q41947874-37C4D2CF-F3C2-45A6-AD07-551CCC3DA7C2Q42509920-34E07D72-9F34-4276-80B9-CB207E39FFA4Q43054920-703DDF0B-45AB-450B-AB6F-2A8581815610Q47951404-1331B0B7-365E-4818-89DF-057A65A382C8Q50063006-0A3DB6A9-7909-49B9-AE60-BD3D1705D62BQ53125855-5DA2D7EC-A649-40EB-8641-48B7D69E7ABDQ55031565-F4B43395-1639-437D-AF91-9A8689A8A2C7Q55424174-305595A9-7253-460A-B1B9-317DF6FF1B33
P2860
Commentary: Oncologic drugs in patients with organ dysfunction: a summary.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Commentary: Oncologic drugs in patients with organ dysfunction: a summary.
@en
type
label
Commentary: Oncologic drugs in patients with organ dysfunction: a summary.
@en
prefLabel
Commentary: Oncologic drugs in patients with organ dysfunction: a summary.
@en
P2093
P1433
P1476
Commentary: Oncologic drugs in patients with organ dysfunction: a summary.
@en
P2093
Andrea A Iannucci
Angela M Davies
Diana Superfin
P304
P356
10.1634/THEONCOLOGIST.12-9-1070
P577
2007-09-01T00:00:00Z